A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

This study is testing a new drug called Tulmimetostat to see how well it fights various advanced cancers and lymphomas. By blocking specific enzymes that help cancer cells grow, researchers hope this treatment can provide a new option for patients when other therapies have stopped working.

You may be eligible if you are at least 18 years old, can perform daily activities independently, and have a specific type of advanced cancer or lymphoma. Doctors will also check that your heart, liver, kidneys, and overall health are stable enough to handle the study treatment.

You will receive the study drug, either alone or with another medication called enzalutamide, to see how it affects your cancer. Throughout the trial, you will have regular check-ups and provide small samples of blood and tumor tissue to help the team understand how the medicine works in your body.

This study is currently recruiting patients at medical centers in Tampa, Florida; Atlanta, Georgia; and Chicago, Illinois. If you are interested, your doctor can help you contact these locations to see if the trial is a good fit for you.